MEASURING & MONITORING RISK USING ANALYTICS

Size: px
Start display at page:

Download "MEASURING & MONITORING RISK USING ANALYTICS"

Transcription

1 MEASURING & MONITORING RISK USING ANALYTICS APRIL 13, HURON CONSULTING GROUP INC.

2 PRESENTERS Brian Bohnenkamp Partner King & Spalding Jack Tanselle Managing Director Huron Consulting Group Jeff Fisher Director Huron Consulting Group HURON CONSULTING GROUP INC.

3 TABLE OF CONTENTS 1 CURRENT LANDSCAPE 4 2 ASSESSING RISKS; DRIVING MONITORING PLANS 13 3 EVOLUTION OF COMPLIANCE ANALYTICS AND CASE STUDIES 19 4 ROADMAP FOR ESTABLISHING AGILE ANALYTIC CAPABILITIES HURON CONSULTING GROUP INC.

4 1 CURRENT LANDSCAPE HURON CONSULTING GROUP INC.

5 RECENT LIFE SCIENCES SETTLEMENTS Company Settlement Year Alleged Conduct Sanofi Pasteur ~$20 million 2017 Pricing Orthofix ~6 million 2017 FCPA Violations Advanced BioHealing $350 million 2017 Kickbacks Teva $519 million 2016 FCPA Violations Forest $38 million 2016 Kickbacks Biocompatibles $36 million 2016 Misbranding Mylan $465 million 2016 Pricing Novartis $16 million 2016 Off-Label Promotion Acclarent $18 million 2016 Off-Label Promotion Valeant/Salix $54 million 2016 Kickbacks Genentech/OSI Pharmaceuticals $67 million 2016 Misleading Statements Aegerion ~$40 million settlement reserve disclosed 2016 Off-Label Promotion Pfizer/Wyeth $784 million 2016 Pricing FCPA Violations Olympus $646 million 2016 Kickbacks Novartis $390 million 2015 Kickbacks Warner Chilcott $125 million 2015 Kickbacks Millennium Health $256 million 2015 Kickbacks Johnson & Johnson $25 million 2015 GMP Violations HURON CONSULTING GROUP INC.

6 Companies have spent a lot of time, effort, and resources to comply with PERSPECTIVE FROM THE OIG: GROWING EMPHASIS ON KICKBACKS open payments reporting requirements, and I would recommend that [they] capitalize on those investments. Mary Riordan, OIG Senior Counsel, from her Keynote Address at the 2015 Pharmaceutical Compliance Congress Ms. Riordan went on to challenge manufacturers: What types of financial relationships does your company have with prescribers, purchasers, or recommenders of your products? Are there legitimate business needs for those relationships? Are there processes and controls in place to make sure these relationships are lawful and don t run afoul of kickback statutes? HURON CONSULTING GROUP INC.

7 TRENDING RISK AREAS Speaker programs Meals Value-added services Consulting arrangements Equipment loans Grants and donations Arrangements with specialty pharmacies Arrangements with PBMs and payors Interactions with patients and patient advocacy groups Coupons and co-pay cards HURON CONSULTING GROUP INC.

8 GROWING NUMBER OF RELEVANT AUTHORITIES TO CONSIDER IN ASSESSING POTENTIAL RISKS Federal Anti-Kickback Statute FDA laws and regulations (e.g., advertising and promotion, clinical trials, adverse event, GMPs) False Claims Act Foreign Corrupt Practices Act Drug price reporting laws and regulations (e.g., Medicaid Best Price) Prescription Drug Marketing Act (samples) Executive Branch ethics laws (apply to interactions with VA and DoD) Open Payments/Sunshine Act State State kickback prohibitions and false claims acts State gift bans and compliance program laws State transparency laws State consumer protection laws and restrictions on unfair trade practices State government ethics laws and lobbying requirements/restrictions Other important non-legal authorities Industry codes of conduct (PhRMA Code, AdvaMed Code) Institutional conflicts of interest policies HURON CONSULTING GROUP INC.

9 BIG DATA ON THE SCENE... Gov t reliance on data analytics continues to increase Federal law enforcement encouraged to use data analytics prospectively to identify potential fraud and abuse Open Payments and Medicare Provider Utilization and Payment Data databases available for sophisticated analytics HURON CONSULTING GROUP INC.

10 ... FOR EVERYONE TO USE HURON CONSULTING GROUP INC.

11 EVOLVING EXPECTATIONS FOR COMPLIANCE PROGRAMS Federal enforcement authorities are increasingly focused on compliance program operational effectiveness. In November 2015, DOJ hired Hui Chen, the first ever DOJ Compliance Counsel, to provide guidance to prosecutors on compliance program effectiveness. In February 2017, DOJ published guidelines to evaluate corporate compliance programs HURON CONSULTING GROUP INC.

12 EVOLVING EXPECTATIONS FOR COMPLIANCE PROGRAMS Risk Assessment and Mitigation Process (RAMP) requirements have become boilerplate provisions in CIAs with HHS-OIG. In March 2017, OIG/HCCA published the Resource Guide for Measuring Compliance Program Effectiveness HURON CONSULTING GROUP INC.

13 2 ASSESSING RISKS; DRIVING MONITORING PLANS HURON CONSULTING GROUP INC.

14 RISK ASSESSMENT AND MITIGATION PROCESS ( RAMP ) A RAMP program is the backbone of a sustainable, effective compliance program, creating a repeating cycle of continuous improvement through risk mitigating activity. RISK ASSESSMENT (annual and ad hoc) Mitigation planning driven by risk assessment output Continuous Improvement* AUDITING & MONITORING Traditional audits For cause audits Live/field monitoring Records reviews Analytics monitoring *Continuous Improvement: Management responses Evolving policies and procedures Improved/increased training Improved/increased communications Business ownership of compliance Routine, integrated dialogue Mitigation output and external forces serve as risk assessment inputs External Forces: Hotline, Investigations, Changing Regulations, Market Conditions HURON CONSULTING GROUP INC.

15 RISK ASSESSMENT PROCESS Risk Activity Catalogue Assess Current Controls Risk Scoring (prioritize) Create A&M Plans Re-assess Refine Repeat Create a catalogue of all potential compliance risk activities Include risk categories as well as specific risk areas Assess controls related to each risk activity Meet with risk activity stakeholders to learn needs and concerns Use criteria that may include: current enforcement, current controls, levels of spending, frequency and volume of activity The risk ranking drives auditing and monitoring plans, including dashboards and reports needed Evaluate the progress of mitigation efforts Continue dialogue w/ stakeholders and assess for changes Repeat at least annually HURON CONSULTING GROUP INC.

16 RISK ACTIVITY CATALOGUE EXAMPLES HURON CONSULTING GROUP INC.

17 RISK SCORING MODELS EXAMPLE Area for Review Current Enforcement Activity Level of Spending Frequency of Activity Existing Controls Total Sales & Marketing Speaker Programs Third-Party Arrangements Consulting/Ad Boards Promotional Materials Gifts& Business Courtesies Time & Expense Reporting Minimum Minimal risk with strong corporate compliance controls 0 Medium Maximum Current or historical enforcement action with some compliance controls High risk due to current enforcement action and/or high levels of scrutiny outside the organization. Action (or inaction) may impact multiple areas within the organization HURON CONSULTING GROUP INC.

18 RISK ASSESSMENT: CRITICAL SUCCESS FACTORS Risk assessments, and the mitigation plans driven by the output from them, must be jointly developed and implemented in partnership with business leadership. Risk activities must be identified and scored on a relative scale for prioritization. Key Performance Indicators ( KPIs ) must be developed to continually measure the effectiveness of risk-mitigation actions. It can be challenging to prove the effectiveness of a compliance program, given the objective is often to try to prove a negative: the risk-mitigation actions must be working since the bad event hasn t occurred. The solution lies partly in a company s ability to develop meaningful KPIs that act as surrogates to predict the success or failure of your compliance initiatives HURON CONSULTING GROUP INC.

19 3 EVOLUTION OF COMPLIANCE ANALYTICS AND CASE STUDIES HURON CONSULTING GROUP INC.

20 OPPORTUNITY: USING ANALYTICS FOR DECISION MAKING Life Sciences companies are exploring how to best create an analytics platform that provides the following: Summary and detailed analysis of operational and financial data Algorithms to measure and visually display operational and compliance risk Proactive alerts that identify risk trends Analytic views that meet customized needs of individual business users Flexibility and scalability to meet needs as demands increase HURON CONSULTING GROUP INC.

21 BARRIERS: USING ANALYTICS FOR DECISION MAKING Implementing a compliance analytic and dashboard application presents significant challenges, including: Identifying source systems and data elements that have relevance to measure compliance Identifying measures that can display compliance risk Determining requirements and design for compliance management and dashboard application Incorporating best practices and industry current practices, as applicable, into the design Creating and maintaining required data mart and visualization application HURON CONSULTING GROUP INC.

22 EVOLUTION: MORE PROACTIVE & AUTOMATED Retrospective Monitoring Characterized by: Highly/ entirely manual processes Time, resource, and costintensive Random sampling & reporting = limited insights Resources less focused on action; consumed by process Redundancy in analyses Time to structure data Time to generate ad hoc reports Time to execute monitoring activities GOAL Proactive Monitoring Characterized by: Highly/entirely automatic analyses & reporting Reporting & metrics that are time, resource, and cost-effective Complete analysis = comprehensive insights Resources focused on analysis and action Is it structured so we can create the analysis we want? How much is it going to cost? How long is it going to take? Does the data exist? Can we access it? Tools Web-Based Forms Data Aggregation Data Visualization A long-term solution that flexes with your needs Embeds subject matter expertise in an automated platform HURON CONSULTING GROUP INC.

23 SAMPLE DATA SETS Data Set Sample Analyses Examples of Business Value Stakeholders Expense Data HCP Target List HCP Consultant Spend Promotional Programs Attendee List Clinical Trial Data Training Records Identification of Expense Outliers Per Attendee Meal Spend vs. Policy Requirements Appropriateness of Physician Specialty Targeting e.g. onlabel/off-label; NSAID Rx volume HCPs Consultant Spend vs. Policy Cap List of HCPs that attend multiple programs on the same product, with frequency Annual snapshot of compliance with FDAAA and NIH requirements Personnel training compliance statistics Identify total vendor spend via expense reporting to inform negotiations Identify potentially excessive spenders and take action centrally Faster decisions to include/exclude HCPs nominated by the field for detailing Enhanced promotional targeting (e.g. pain specialists, rheums, GP/FP, other audiences) Refinement of field resource allocation Strategic allocation of HCP engagement based on transparency to potential cap limitations Increase market spend efficacy by knowing when to refrain from inviting an HCP to multiple programs on the similar topics Sourcing potential new drug candidates Identify highest-enrolling sites for a given TA Increase knowledge development of company products and practices Compliance, Marketing, Medical Compliance, Sales, Sales Operations Compliance; all who engage HCPs Compliance, Marketing, Sales Operations Clinical, Commercial, Regulatory, R&D Compliance, Legal/HR HURON CONSULTING GROUP INC.

24 OTHER EXAMPLES Multi-Source Analysis HCP Risk Scoring MSL Risk Scoring RBM Risk Scoring Sales Rep Risk Scoring Competitor HCP Spend Analysis Compliance Value Business Value Stakeholders Proactively identify inappropriate relationships Proactively identify candidates for increased monitoring and records audits Identify spend outliers compared to competitors Provides full picture of information to assess relationship with HCP Proactive monitoring of potential risks such as offlabel promotion, kickbacks, misbranding, etc. may mitigate suspicion, investigations, hefty fines, and loss of brand value. Determine whether reallocation of spend is necessary Compliance, Marketing, Sales, Sales Operations Compliance, Sales, Sales Operations Compliance, Marketing, Sales, Sales Operations HURON CONSULTING GROUP INC.

25 CASE STUDY #1: OPEN PAYMENTS PEER ANALYSIS The Requirement The commercial group wanted to gain insights into the promotional activities of their peers. The Analysis Commercial and Compliance collaborated on the project to ensure adherence to business goals and company policies. Key analytics were created to provide insights into speaker programs and HCP utilization. The Results Compliance was able to discover key insights into peer makeup of speaker programs and HCP utilization HURON CONSULTING GROUP INC.

26 COMPLIANCE MONITORING WITH OPEN PAYMENTS: Comparing HCP Utilization Viewing how other peer companies engage HCPs that your company also utilizes can help to identify optics seen by government and the public HURON CONSULTING GROUP INC.

27 CASE STUDY #2: MEDICARE PART D TRENDS The Requirement The compliance group wanted to gain an understanding, using publicly available data, of the prescribing patterns of the HCPs they engaged. The Analysis Open Payments were analyzed in relation to Part-D data. Commercial and Compliance collaborated closely to ensure adherence to company policies, important in a sensitive exercise of analyzing HCP prescribing patterns. The Results Compliance was able to identify HCPs outliers warranting further analysis due to potentially worrisome prescribing patterns HURON CONSULTING GROUP INC.

28 COMPLIANCE MONITORING WITH OPEN PAYMENTS: Sales Correlated with Fee Payments Sales information (e.g. Part-D) can be correlated with physician fee payments to identify appearance of potential inappropriate influence HURON CONSULTING GROUP INC.

29 CASE STUDY #3: SPEAKER PROGRAM MONITORING The Requirement The compliance group wanted to track speaker program metrics in real-time. The Analysis Monitoring dashboards were created to provide real-time views of speaker programs, monitoring results, and investigations. The Results Compliance was able to efficiently identify trends in speaker program policy violations resulting in a rapid response which included retraining and a shift in attendee invitation practices HURON CONSULTING GROUP INC.

30 COMPLIANCE MONITORING OF SPEAKER PROGRAMS Program Monitoring Summary Tracking findings and corrective actions associated with monitoring Speaker Programs figures to remain a staple activity to include in monitoring dashboards HURON CONSULTING GROUP INC.

31 COMPLIANCE MONITORING SPEAKER PROGRAMS Attendee Count Distribution Analysis of attendees can identify programs with low utilization HURON CONSULTING GROUP INC.

32 CASE STUDY #4: SALES FORCE EXPENSE MONITORING The Requirement The compliance group wanted to gain insights into the expense activity of sales reps and the organization s association with vendors who present policy or perception risks. The Analysis Analytics were created to monitor T&E expenses to identify vendors and key metrics. The Results Compliance was able to identify several risks in expense meal venues and per-person costs HURON CONSULTING GROUP INC.

33 COMPLIANCE MONITORING WITH CONCUR Top Specialty Spending Using analytics to inspect Concur expenses can identify potential HCP attendees with inappropriate specialties HURON CONSULTING GROUP INC.

34 CASE STUDY #5: PRICING & CONTRACTING ACCRUALS The Requirement The Government Program group wanted reliable, repeatable, and efficient analysis of their monthly pricing and liabilities. The Analysis Analytics were created to seamlessly integrate with the GP systems and processes, tailored to the organizations unique needs and variance drivers. The Results Compliance was able to significantly reduce the burden of month- and quarter-end analysis of GP liabilities, and create informative, actionable management reports HURON CONSULTING GROUP INC.

35 SAMPLE: QUARTERLY AMP SUMMARY REPORT HURON CONSULTING GROUP INC.

36 CASE STUDY #6: CALIBRATING FAIR MARKET VALUE The Requirement The commercial group wanted to gain insights into the compensation peers were providing to HCPs. The Analysis Analytics were created to statistically analyze the distribution of payments for various types of HCP engagements, including speaking and consulting for both CME and non-cme activities. The Results Compliance was able to identify how their own compensation compared to peers HURON CONSULTING GROUP INC.

37 COMPLIANCE MONITORING WITH OPEN PAYMENTS FMV of Speaker Program Payments Open Payments data can be used to compare your speaker program payments against peers, giving insight into your FMV range HURON CONSULTING GROUP INC.

38 CASE STUDY #6: RETURN ON EDUCATION The Requirement The commercial group wanted to move towards optimizing total spend and distribution of spend to optimize return on education investment with speaker programs. The Analysis Commercial and Compliance collaborated on the project to ensure adherence to business goals and company policies. Key analytics were created to provide insights into speaker programs and HCP utilization. The Results Commercial and Compliance were able to jointly agree on shifts to be made in speaker program content, speaker selection, and regional spend while enhancing risk mitigation HURON CONSULTING GROUP INC.

39 RETURN ON EDUCATION Event Location Pattern Analysis Inputs Product sales Category sales SPB events Outputs Potential for more targeted education SBP overlay in a click-through national dashboard Implications Resource over/underdeployment Restricted speaker access environments Suggestion of content requirements HURON CONSULTING GROUP INC.

40 4 ROADMAP FOR ESTABLISHING AGILE ANALYTIC CAPABILITIES HURON CONSULTING GROUP INC.

41 STRATEGIC CONSIDERATIONS Consider your organization s unique vision statement and goal for conducting analyses For example: To identify positioning vis-a-vis competitors, and to draw insights that inform both compliance and HCP engagement functions Consider a governance document to guide analytics work at your company Identify stakeholders across all functional areas and build consensus around a unified team Evaluate internal capability to: Interpret analyses from both a compliance and commercial perspective Construct effective, informative analyses, including technology solutions Manage the project in a controlled manner, taking into account the numerous stakeholder sensitivities HURON CONSULTING GROUP INC.

42 DETERMINE REQUIREMENTS: BUSINESS, COMPLIANCE, FUNCTIONAL AND DATA Identify functional, business, and compliance requirements then combine with data requirements to help the team develop an end-to-end compliance and dashboard application Specific work activities and deliverables for the requirements gathering phase are provided in the table below. Activity Work Steps Deliverables Identify Business/ Functional Requirements Develop and Deploy Proof-of- Concept Application Review existing compliance policies and other documentation Identify business, functional, and compliance analysis requirements Conduct stakeholder interviews/workshops to determine functional/business requirements Create analysis views for proof-of-concept application Create risk management algorithms Identify required data elements Evaluate completeness and accuracy of data capture and identify gaps and solutions to remediate them Develop Functional Design Specification Develop requirements traceability matrix Develop data-based visualizations in accordance with the Functional Design Specification Review functionality with project team Incorporate feedback into functionality Implement Proof-of Concept Application Business/Functional Requirements Traceability matrix documenting business and regulatory requirements Draft Functional Design Specification for Proof-of-Concept Application Updated Functional Design Specification Proof-of-Concept Application HURON CONSULTING GROUP INC.

43 EXAMPLE METHODOLOGY Phase I Phase II Phase III Phase IV Design/Enhance Risk Assessment Process Determine Data and Risk Measures Design Dashboards and Infrastructure Replicate for Global Rollout Objective(s) Key Activities Key Deliverables 1. Create initial designs for visualizations and dashboards 2. Identify source data requirements that will support visualization and dashboard designs 1. Utilize risk assessment visualization library as a baseline to help users describe risk visualization requirements 2. Work with client stakeholders to identify visualization requirements 3. Create initial designs for dashboards and visualizations 4. Design drill-down, roll-up, and data amplification scenarios and designs 5. Define alert criteria 6. Identify source data elements for visualizations 7. Review source systems to ensure data elements are resident within the source systems 8. Work with client IT to create approach to capture data elements not currently stored in source systems Dashboard mock-up diagrams Dashboard data requirements, refresh processes, and ongoing support recommendations HURON CONSULTING GROUP INC.

44 THANK YOU

COMBATING BRIBERY & CORRUPTION THROUGH INFORMATION INTELLIGENCE

COMBATING BRIBERY & CORRUPTION THROUGH INFORMATION INTELLIGENCE COMBATING BRIBERY & CORRUPTION THROUGH INFORMATION INTELLIGENCE SETTING THE CONTEXT Anti-bribery and corruption continues to be a high priority Sustained enforcement and increasing regulator expectations,

More information

Operational Considerations for Transparency. September 2011

Operational Considerations for Transparency. September 2011 Operational Considerations for Transparency September 2011 Current Global Regulatory Trends Type of Regulations/ Guidance Company s obligations Scope Sanctions/ Penalties State Laws Promotional spend reporting

More information

Off-label, Anti-Kickback, and Other Risks within Speaker Program Compliance

Off-label, Anti-Kickback, and Other Risks within Speaker Program Compliance Off-label, Anti-Kickback, and Other Risks within Speaker Program Compliance Neal J. Rafferty US Compliance Officer Merz North America neal.rafferty@merz.com The content & statements in this presentation

More information

Auditing: A Panel Discussion of Evolving Compliance Strategies

Auditing: A Panel Discussion of Evolving Compliance Strategies Auditing: A Panel Discussion of Evolving Compliance Strategies Ann E Lewis, VP and Senior Counsel, US Healthcare Law Compliance (Bristol-Myers Squibb) Monica Jonhart, Director, Auditing, US Healthcare

More information

Mini Summit 11 Best Practice in HCP / HCO Management to Reduce Compliance Risk and Enhance Efficiency

Mini Summit 11 Best Practice in HCP / HCO Management to Reduce Compliance Risk and Enhance Efficiency Mini Summit 11 Best Practice in HCP / HCO Management to Reduce Compliance Risk and Enhance Efficiency 18 th ASIA PACIFIC PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS September 10-12,

More information

New Trends in the Use of Fair Market Value Concepts. PCF Disclosure, Transparency, and Aggregate Spend Conference February 6, 2014

New Trends in the Use of Fair Market Value Concepts. PCF Disclosure, Transparency, and Aggregate Spend Conference February 6, 2014 New Trends in the Use of Fair Market Value Concepts PCF Disclosure, Transparency, and Aggregate Spend Conference February 6, 2014 Agenda Today s Speakers 4 Today s Discussion Topics 6 Question and Answer

More information

Advanced Contracting Course

Advanced Contracting Course Advanced Contracting Course Stephanie Levin, AD, Commercial Data Acquisition & Scouting Bayer Healthcare Leslie Yendro, VP Business Development Avella Specialty Pharmacy Agenda Introduction Common Types

More information

Off-Label Promotion: Risks, Controls and Assessment

Off-Label Promotion: Risks, Controls and Assessment 7 th th Annual National Pharmaceutical Congress November 9, 2006 Off-Label Promotion: Risks, Controls and Assessment John T. Bentivoglio Co-Leader FDA/Healthcare Group jbentivoglio@kslaw.com 202.626.5591

More information

Fourth Annual Pharmaceutical Regulatory and Compliance Congress

Fourth Annual Pharmaceutical Regulatory and Compliance Congress Fourth Annual Pharmaceutical Regulatory and Compliance Congress Preconference I A Compliance Primer for the Pharmaceutical Sector Michael P. Swiatocha November 12, 2003 Agenda for Preconference I Introduction

More information

PCF Analytics Workshop

PCF Analytics Workshop PCF Analytics Workshop Asking the Right Risk Questions to Power Your Advanced Analytics Strategy November 7, 2018 Welcome! 19th Annual Pharmaceutical and Medical Device Compliance Congress Preconference

More information

Declaration Pursuant to California Health and Safety Code (e)

Declaration Pursuant to California Health and Safety Code (e) Declaration Pursuant to California Health and Safety Code 119402(e) Bausch + Lomb is committed to upholding the highest standards of business conduct and ethics in its relationships with its customers,

More information

Compliance on the Road: Government and Industry Efforts to Monitor Field Force

Compliance on the Road: Government and Industry Efforts to Monitor Field Force Page 1 of 6 May 2011 Volume 7 Number 9 Compliance on the Road: Government and Industry Efforts to Monitor Field Force Compliance By Heather McCollum, Senior Consultant, Polaris Management Partners, New

More information

WORKSHOP B Monitor MSL and Field Force Compliance

WORKSHOP B Monitor MSL and Field Force Compliance WORKSHOP B Monitor MSL and Field Force Compliance Jeremy Lutsky Sr. Legal & Compliance Counsel Theravance Biopharma US, Inc. Alison Benincasa Associate Director, Specialty Markets Compliance Christine

More information

Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders

Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders Daniel Snyder, PhD Medical Director, Neurology North America Medical Affairs Ipsen Biopharmaceuticals, Inc.

More information

Building a Culture of Compliance with Your Sales Force

Building a Culture of Compliance with Your Sales Force Building a Culture of Compliance with Your Sales Force Lora Posey, Mission Pharmacal Mark Jara, RxS LLC 2018 Sharing Alliance All rights reserved Building A Culture Of Compliance With Your Sales Force

More information

Acceleron Pharma Inc. Code of Business Conduct and Ethics

Acceleron Pharma Inc. Code of Business Conduct and Ethics I. INTRODUCTION Acceleron Pharma Inc. Code of Business Conduct and Ethics (Amended & Restated as of March 1, 2018) This Code of Business Conduct and Ethics ( Code ) provides a general statement of the

More information

Speaker Programs Risks and Rewards. Presented by: Alan G. Minsk Partner, Arnall Golden Gregory LLP and Alliance Legal Counsel

Speaker Programs Risks and Rewards. Presented by: Alan G. Minsk Partner, Arnall Golden Gregory LLP and Alliance Legal Counsel Speaker Programs Risks and Rewards Presented by: Alan G. Minsk Partner, Arnall Golden Gregory LLP and Alliance Legal Counsel alan.minsk@agg.com What is a Speaker Program! Company-Sponsored Program! Typically,

More information

ARNOLD & PORTER UPDATE

ARNOLD & PORTER UPDATE ARNOLD & PORTER UPDATE Pharmaceutical Sales and Marketing Practices Government Also Cautions Medical Device Companies on Such Practices April 2003 On April 28, 2003, the Office of Inspector General, Department

More information

American Academy of Orthopaedic Surgeons 2010 Annual Meeting

American Academy of Orthopaedic Surgeons 2010 Annual Meeting American Academy of Orthopaedic Surgeons 2010 Annual Meeting Off-Label Device Use: When Clinical Need Outpaces Regulatory Approval The Legal Parameters of Off-Label Use March 10, 2010 Kathleen McDermott

More information

The power of the Converge platform lies in the ability to share data across all aspects of risk management over a secure workspace.

The power of the Converge platform lies in the ability to share data across all aspects of risk management over a secure workspace. Converge Platform The transition to value-based care is breaking down the barriers between the CNO, CMO, and Chief Legal Counsel in managing enterprise risk. It s time to take a proactive systems approach

More information

Does your organization have a designated Compliance Officer? a. Yes b. No c. Don't know

Does your organization have a designated Compliance Officer? a. Yes b. No c. Don't know Developing a Compliance Workplan Uri Bilek Feldesman Tucker Leifer Fidell LLP Does your organization have a designated Compliance Officer? a. Yes b. No c. Don't know Does your organization have an established

More information

Transparency as a Good Business Practice

Transparency as a Good Business Practice Transparency as a Good Business Practice Exploring How Transparency Can Drive Best Practices in Business Strategy August 2017 Polaris Management Partners Agenda Compliance Trends 2017-2018 Deriving Strategic

More information

EXAMINE THE BREAKDOWN OF FEES IN MANAGED MARKETS AND SPECIALTY PHARMACIES

EXAMINE THE BREAKDOWN OF FEES IN MANAGED MARKETS AND SPECIALTY PHARMACIES EXAMINE THE BREAKDOWN OF FEES IN MANAGED MARKETS AND SPECIALTY PHARMACIES CBI 4TH ANNUAL FMV CONGRESS March 28, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS John Moose, CPA, ABV Director

More information

Speaker Programs February 8, 2017 Shauna C. Liu Richard F. Eschle, Pharm.D., J.D.

Speaker Programs February 8, 2017 Shauna C. Liu Richard F. Eschle, Pharm.D., J.D. Speaker Programs 2017 February 8, 2017 Shauna C. Liu Richard F. Eschle, Pharm.D., J.D. 1 Disclaimer The opinions expressed in this presentation are mine and do not necessarily reflect of those of my employer.

More information

Mini Summit XI: Third Party Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment

Mini Summit XI: Third Party Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment Mini Summit XI: Third Party Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment Shanghai 16:00 17:15 14 September, 2017 Disclaimer Please note that the views and opinions

More information

Gross-to-Net Estimates and Accruals - Master Class

Gross-to-Net Estimates and Accruals - Master Class Gross-to-Net Estimates and Accruals - Master Class Mike Makovec, Audit Senior Manager, Deloitte & Touche LLP Walt Worsham, Senior Manager, Deloitte & Touche LLP Brad Schulte, Senior Manager, Deloitte &

More information

Triple C Housing, Inc. Compliance Plan

Triple C Housing, Inc. Compliance Plan Triple C Housing, Inc. Compliance Plan Adopted by Board of Directors on draft November 13, 2014 Overview Triple C Housing, Inc. is committed to its consumers, employees, contractual providers, vendors,

More information

Helping Pharmas Manage Compliance Risks for Speaker Programs

Helping Pharmas Manage Compliance Risks for Speaker Programs COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively

More information

Optimize Government Pricing Agreements for Maximum Returns

Optimize Government Pricing Agreements for Maximum Returns Optimize Government Pricing Agreements for Maximum Returns 19 th Annual Medicaid and Government Pricing Congress We partner with our clients in the Life Sciences & Healthcare industries to provide direct

More information

Compliance Plans. Kelly S. McIntosh July 20, 2017

Compliance Plans. Kelly S. McIntosh July 20, 2017 Compliance Plans Kelly S. McIntosh July 20, 2017 Roadmap The importance of compliance and compliance programs Common compliance issues know your risk areas! Guidance for drafting or updating your compliance

More information

Benchmarking Compliance Programs. Bret S. Bissey, MBA, FACHE, CHC, CMPE, Senior Vice President, Compliance Services, MediTract

Benchmarking Compliance Programs. Bret S. Bissey, MBA, FACHE, CHC, CMPE, Senior Vice President, Compliance Services, MediTract Benchmarking Compliance Programs Bret S. Bissey, MBA, FACHE, CHC, CMPE, Senior Vice President, Compliance Services, MediTract Health Care Compliance Association INDIANAPOLIS, IN Regional Conference September

More information

Effective Risk Management With AML Risk Assessment. January 25, 2017

Effective Risk Management With AML Risk Assessment. January 25, 2017 Effective Risk Management With AML Risk Assessment January 25, 2017 2017 2017 Crowe Crowe Horwath Horwath LLP LLP Agenda Regulatory Trends in Risk Assessment Crowe Approach to Anti-Money Laundering (AML)

More information

Advanced Issues in Commercial Compliance. Tenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum November 11, 2009

Advanced Issues in Commercial Compliance. Tenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum November 11, 2009 Advanced Issues in Commercial Compliance Tenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum November 11, 2009 Source Data for Monitoring & Compliance Using Core Transactional

More information

PRECONFERENCE: AGGREGATE SPEND AND DISCLOSURE 101

PRECONFERENCE: AGGREGATE SPEND AND DISCLOSURE 101 PRECONFERENCE: AGGREGATE SPEND AND DISCLOSURE 101 The Basics of Disclosure/Aggregate Spend Technology Solutions Don Soong Sr Director, Compliance Solutions Cegedim March 9 th, 2011 THIS IS THE INTRODUCTION

More information

Managing Third-Party Relationships

Managing Third-Party Relationships Managing Third-Party Relationships PCC Canada 2017 6 June 2017 Presented by Stephan Ekmekjian and Darren Jones Looking ahead to 2017 & beyond Accountability Integration of compliance and business Business

More information

Real World Evidence and Implications to Value-based Contracting

Real World Evidence and Implications to Value-based Contracting Real World Evidence and Implications to Value-based Contracting Panel Introductions Mark DeWyngaert, PhD Managing Director Huron Consulting Group Susan Lee Partner, Washington, D.C. Hogan Lovells BJ D

More information

Compliance Program Effectiveness Guide

Compliance Program Effectiveness Guide Compliance Program Effectiveness Guide June 2017 This Guide is a comparison of: Compliance Program Elements New York State, Social Services Law 363-D Office of Inspector General (OIG) Compliance Program

More information

China Compliance Roundtable RDPAC Legal and Compliance Working Group Best Practices Task Force

China Compliance Roundtable RDPAC Legal and Compliance Working Group Best Practices Task Force China Compliance Roundtable RDPAC Legal and Compliance Working Group Best Practices Task Force September 11, 2012 Agenda 1. Status Report the RDPAC Code 2. Emerging Trends China 2012 1. General 2. T&E

More information

The Eight Elements of a Compliance Plan and What Has Changed

The Eight Elements of a Compliance Plan and What Has Changed The Eight Elements of a Compliance Plan and What Has Changed Lori Laubach, CHC Principal Thursday, June 9 8:30AM 10AM 1 The material appearing in this presentation is for informational purposes only and

More information

Anti-bribery corporate policy

Anti-bribery corporate policy Anti-bribery corporate policy 1. Scope and purpose of this guideline One of the key factors and reasons for the favorable reputation and image of Sb Accounting & Consulting is its ability and will to conduct

More information

2/12/2014. Physician Hospital Integration 1. Physician-Hospital Integration Compliance Considerations. Agenda

2/12/2014. Physician Hospital Integration 1. Physician-Hospital Integration Compliance Considerations. Agenda Physician-Hospital Integration Compliance Considerations Frank E. Sheeder III Chair, Health Care Enforcement and Compliance Practice DLA Piper LLP (US) 214-743-4560 frank.sheeder@dlapiper.com Agenda 1.

More information

Commercial Pricing and Contracting 101

Commercial Pricing and Contracting 101 Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai

More information

Implementing a Compliance Monitoring Program. January 29, 2014

Implementing a Compliance Monitoring Program. January 29, 2014 Implementing a Compliance Monitoring Program January 29, 2014 1 Agenda 1. Mission and Purpose 2. Scope 3. Situational Analysis 4. Best Practices 5. Questions Mission and Purpose 3 Mission and Purpose Mission

More information

NATIONAL INSTRUMENTS VISUALIZES GROWTH WITH XACTLY

NATIONAL INSTRUMENTS VISUALIZES GROWTH WITH XACTLY NATIONAL INSTRUMENTS VISUALIZES GROWTH WITH XACTLY THE CHALLENGE National Instruments is a technology company based in Austin, TX that aims to equip engineers and scientists with systems that accelerate

More information

Conducting a Compliance Audit or Review Key Issues

Conducting a Compliance Audit or Review Key Issues Conducting a Compliance Audit or Review Key Issues Prepared By: Ethan E. Rii, Esq. Partner Katten Muchin Rosenman LLP ethan.rii@kattenlaw.com Do you have an effective compliance program? Competitive advantages

More information

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Amgen GLOBAL CORPORATE COMPLIANCE POLICY 1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract

More information

CODE OF CONDUCT DESCRIPTION PRINCIPLES POLICIES AND DEFINITIONS

CODE OF CONDUCT DESCRIPTION PRINCIPLES POLICIES AND DEFINITIONS CODE OF CONDUCT DESCRIPTION Schneider has adopted the following Code of Conduct ( Code ) to apply to Schneider s directors, officers, managers and associates. While no code or policy can anticipate every

More information

PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM

PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM JIM SHEEHAN(EDPA) Jim.Sheehan@USDOJ.gov 215 861-8301 www.usao-edpa.com DISCLAIMER My opinions, not official

More information

Optum Performance Analytics

Optum Performance Analytics Optum Performance Analytics A unified health care data and analytics platform Photo to come Optum Performance Analytics Position your organization for success with Optum Performance Analytics Dynamic health

More information

The FIFTEENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS

The FIFTEENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS The FIFTEENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS Pre-Conference II: Innovations in Auditing and Monitoring 11.03.14 Presented by L. Stephan Vincze Innovations in Auditing and Monitoring

More information

Managing Risk with Third Parties and Strategic Partners

Managing Risk with Third Parties and Strategic Partners Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Paul J. Silver Managing

More information

Convercent All Rights Reserved.

Convercent All Rights Reserved. Aligning Culture and Governance for Better Compliance A new approach to Governance, Risk and Compliance that creates better policies and more engaged employees to reduce incidents CONTENTS 4 5 5 7 8 Better

More information

3/21/2017. How and when should you leverage internal audit? March 28, Agenda. What are your initial thoughts on internal audit?

3/21/2017. How and when should you leverage internal audit? March 28, Agenda. What are your initial thoughts on internal audit? How and when should you leverage internal audit? March 28, 2017 Agenda Internal Audit foundation 3 lines of defense Trends in consultative & value enhancement work Why you should care Key takeaways 2 What

More information

Verifying Compliance Program Effectiveness in Managed Care

Verifying Compliance Program Effectiveness in Managed Care 1 Verifying Compliance Program Effectiveness in Managed Care Cornelia M. Dorfschmid, Executive Vice President Rita Isnar, Senior Vice President F E B R U A R Y 8, 2 0 1 1 COPYRIGHT 2011. SERVICES, LLC.

More information

Innovative Approaches to Saving Patients Money on Prescription Drug Costs

Innovative Approaches to Saving Patients Money on Prescription Drug Costs Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices

More information

CODE OF CONDUCT. (As Amended June 11, 2015)

CODE OF CONDUCT. (As Amended June 11, 2015) CODE OF CONDUCT (As Amended June 11, 2015) 1. INTRODUCTION Employees of Facebook, Inc., or any of its affiliates or subsidiaries, ( Facebook ) and others performing work for Facebook or on its behalf,

More information

Demonstrating and Creating Value with Analytics. John Hendricks & Betsy McVay

Demonstrating and Creating Value with Analytics. John Hendricks & Betsy McVay Demonstrating and Creating Value with Analytics John Hendricks & Betsy McVay 15th largest nonprofit health system 15 hospitals, 8 regions 88 Communities served by 280 physician clinics 14 community network

More information

Sunshine Act and Beyond: Improving Policies and Strategies

Sunshine Act and Beyond: Improving Policies and Strategies Helping companies identify and manage their compliance and commercial risk. C O M P L I A N C E IMPLEMENTATION SERVICES Sunshine Act and Beyond: Improving Policies and Strategies Presented by Vahan Minassian,

More information

August 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

August 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 August 25, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Docket No. FDA-2014-D-0758-0001 Draft Guidance for Industry on Distributing

More information

{ { { Bona Fide Service Fees and Fair Market Value. Managed Services Operations. Compliance & Risk Advisory Services. Business Intel Products

{ { { Bona Fide Service Fees and Fair Market Value. Managed Services Operations. Compliance & Risk Advisory Services. Business Intel Products { { { Managed Services Operations Compliance & Risk Advisory Services Business Intel Products Bona Fide Service Fees and Fair Market Value June 2015 Results from an Industry Survey CIS-PARTNERS.COM 2 BONA

More information

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical

More information

What should your compliance function look like?

What should your compliance function look like? From Start-Up to IPO How to Design and Build a Compliance Program From Scratch Dominic F. Perella Sean Coutain October 2017 What should your compliance function look like? Start With the Legal Frameworks

More information

CLEAR GOAL. Satisfy Regulatory Demands. Mitigates Current Risk Effectively. Provides Meaningful Information About Program Effectiveness

CLEAR GOAL. Satisfy Regulatory Demands. Mitigates Current Risk Effectively. Provides Meaningful Information About Program Effectiveness Catalog # 3 Regulatory Interconnected 4 Growth Hyper Building Predictive Monitoring Capabilities SCCE Conference October 205 Las Vegas, Nevada CEB Compliance & Ethics Leadership Council Project # 4365

More information

Presentation Overview

Presentation Overview How to Reasonably & Effectively Implement Compliance Programs for Small Group Physician Practices Andrea Merritt, Director of Compliance & Audit Services Ashlie Heald, Compliance Specialist Nova Compliance

More information

What is Compliance? Compliance Preventative Medicine for Your Practice. Commit to consistency. Commit to correctness. Commit to communication

What is Compliance? Compliance Preventative Medicine for Your Practice. Commit to consistency. Commit to correctness. Commit to communication Compliance Preventative Medicine for Your Practice Alicia Shickle CPC, CPCO, CPPM Director Compliance Division AAPC What is Compliance? Commit to correctness Do things right Commit to consistency Do the

More information

Are you Ready to Audit your Aggregate Spend Processes and Systems?

Are you Ready to Audit your Aggregate Spend Processes and Systems? Are you Ready to Audit your Aggregate Spend Processes and Systems? Key Steps You Need to Consider Now October 21, 2010 Eve Costopoulos VP, Chief Ethics & Compliance Officer Eisai Inc. Paul Silver Managing

More information

Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS

Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS Biopharmaceutical Company Communications with Health Care Stakeholders RESULTS OF SURVEYS WITH PAYERS AND PROVIDERS DECEMBER 2017 Executive Summary As biomedical research continues to push into new frontiers

More information

Strategies for Forecasting and Grossto-Net (GTN) Estimates in a Fluid and Fast-Paced Environment

Strategies for Forecasting and Grossto-Net (GTN) Estimates in a Fluid and Fast-Paced Environment Strategies for Forecasting and Grossto-Net (GTN) Estimates in a Fluid and Fast-Paced Environment Gaining efficiencies through E2E Process Optimization March 21, 2016 1 Copyright 2016 Deloitte Development

More information

Physician Compliance Program

Physician Compliance Program Mike Runquist Seriously? Objectives Develop Compliance Program where physician leadership helps drive the process Establish engaged physicians in your audit process Effective methods for compliance education

More information

MODULE I: MEDICARE & MEDICAID GENERAL COMPLIANCE TRAINING

MODULE I: MEDICARE & MEDICAID GENERAL COMPLIANCE TRAINING MODULE I: MEDICARE & MEDICAID GENERAL COMPLIANCE TRAINING 2 0 1 4 A Message From Our CEO and Compliance Officer At PacificSource, we pride ourselves on maintaining a culture of compliance and high ethical

More information

Optum Performance Analytics

Optum Performance Analytics Optum Performance Analytics A unified health care data and analytics platform Photo to come Dynamic health care market forces, fueled by delivery and payment reform, have posed many new and difficult questions

More information

Keywords: fi eld-medical, medical science liaisons, metrics, return on investment, consensus

Keywords: fi eld-medical, medical science liaisons, metrics, return on investment, consensus Measuring performance of field-medical programmes: Medical science liaison metrics consensus Jane Chin Date Received (in revised form): 11th June, 2007 Jane Chin is President of Medical Science Liaison

More information

Delta Dental of Michigan, Ohio, and Indiana. Compliance Plan

Delta Dental of Michigan, Ohio, and Indiana. Compliance Plan Delta Dental of Michigan, Ohio, and Indiana Compliance Plan Procedure #: 420-29 Issue Date: 5/15/2013 Last Revised Date: 5/23/2016 Last Review Date: 5/23/2016 Next Review Date: 5/23/2017 Title: Compliance

More information

INTRODUCTION. Overview of Compliance Program. I. Leadership and Structure. GSK Ethics & Compliance Program US Operations

INTRODUCTION. Overview of Compliance Program. I. Leadership and Structure. GSK Ethics & Compliance Program US Operations GSK Ethics & Compliance Program US Operations INTRODUCTION GlaxoSmithKline (GSK) is one of the world s leading research-based pharmaceutical and healthcare companies. GSK s global mission is to improve

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8

More information

Advanced Strategies in Auditing and Monitoring. Wednesday, November 7, 2018

Advanced Strategies in Auditing and Monitoring. Wednesday, November 7, 2018 Advanced Strategies in Auditing and Monitoring Wednesday, November 7, 2018 Agenda 2 8:00 8:20 Opening remarks and introductions of panel members 8:20 9:00 Understanding of current programs through deep

More information

The Current Paradigm in Data Analysis to Identify Potential Fraud, Waste and Abuse in. Fraud Activities: Current Framework

The Current Paradigm in Data Analysis to Identify Potential Fraud, Waste and Abuse in.  Fraud Activities: Current Framework The Current Paradigm in Data Analysis to Identify Potential Fraud, Waste and Abuse in Medicare Part D HCCA Puerto Rico Regional Annual Conference - May 1, 2014 Olgamarién Castillo Aguiar, J.D. www.abarcahealth.com

More information

GUIDELINES. Corporate Compliance. Kenneth D. Gibbs President & Chief Executive. Martin A. Cammer Senior Vice President & Corporate Compliance Officer

GUIDELINES. Corporate Compliance. Kenneth D. Gibbs President & Chief Executive. Martin A. Cammer Senior Vice President & Corporate Compliance Officer GUIDELINES Corporate Compliance Kenneth D. Gibbs President & Chief Executive Martin A. Cammer Senior Vice President & Corporate Compliance Officer Joyce Leahy Executive Vice President for Legal Affairs

More information

Presentation Overview

Presentation Overview How to Reasonably & Effectively Implement Compliance Programs for Small Group Physician Practices Andrea Merritt, Director of Compliance & Audit Services Ashlie Heald, Compliance Specialist Hall, Render,

More information

Speaker Programs: A Holistic Approach to Managing Risk. CBI Life Sciences Compliance Congress West October 18, 2017

Speaker Programs: A Holistic Approach to Managing Risk. CBI Life Sciences Compliance Congress West October 18, 2017 Speaker Programs: A Holistic Approach to Managing Risk CBI Life Sciences Compliance Congress West October 18, 2017 Presenters Jon Wilkenfeld President at Potomac River Partners Chris Hull Consultant at

More information

Presenters. Overview. Matthew R. Grosvenor. Elizabeth Johnson, MBA, CHC. Elizabeth A. Mills, Esq., MHA

Presenters. Overview. Matthew R. Grosvenor. Elizabeth Johnson, MBA, CHC. Elizabeth A. Mills, Esq., MHA Health Care Compliance Association Remuneration Monitoring Tools Achieve Effectiveness through Systematic Data Analysis April 20, 2015 Presenters Matthew R. Grosvenor Partner, Bennett Thrasher LLP Elizabeth

More information

Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM

Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign

More information

PROTECTING YOUR BUSINESS AND CLIENTS FROM HIGH RISK BROKERS

PROTECTING YOUR BUSINESS AND CLIENTS FROM HIGH RISK BROKERS PROTECTING YOUR BUSINESS AND CLIENTS FROM HIGH RISK BROKERS Webinar 28 March 2018 Today s speakers Paul DiBlasi Director of Product Marketing, Financial Markets Compliance Paul.DiBlasi@actimize.com Brian

More information

Improving Revenue Integrity Through Effective Coding and Denials Management

Improving Revenue Integrity Through Effective Coding and Denials Management Improving Revenue Integrity Through Effective Coding and Denials Management June 1, 2018 HFMA Massachusetts/Rhode Island Chapter Christy Matheson, RHIA, CCS Medical Record Associates, LLC OBJECTIVES: Understand

More information

5/14/2018. Billing and Revenue Integrity How Do We Effectively Audit or Monitor? Today s Agenda. What We Hear as the Revenue Integrity Program Goal

5/14/2018. Billing and Revenue Integrity How Do We Effectively Audit or Monitor? Today s Agenda. What We Hear as the Revenue Integrity Program Goal Billing and How Do We Effectively Audit or Monitor? Lori Laubach, CHC Partner Health Care Consulting Today s Agenda Definition of revenue integrity How is the Government looking at revenue integrity? Revenue

More information

Today s presentation

Today s presentation Mandatory Compliance Programs Brenda Tranchida Vernisha Robinson Program Compliance and Oversight Group November 9, 2010 Health Care Compliance Association Compliance In The Post-Reform World 1 Today s

More information

Managing Speaker Program Compliance Benchmarking and Best Practices

Managing Speaker Program Compliance Benchmarking and Best Practices Managing Speaker Program Compliance Benchmarking and Best Practices 16th Pharmaceutical Compliance Congress and Best Practices Forum October 2015 1 With You Today Moderator Katherine Buckley, Advisory

More information

AmerisourceBergen. J.P. Morgan Healthcare Conference. Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO.

AmerisourceBergen. J.P. Morgan Healthcare Conference. Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO. AmerisourceBergen J.P. Morgan Healthcare Conference Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO January 10, 2017 Cautionary Note Regarding Forward-Looking Statements Certain of the statements

More information

BPL s U.S. Compliance Program

BPL s U.S. Compliance Program January 1, 2015 BPL s U.S. Compliance Program I. Introduction Bio Products Laboratory USA, Inc. ( BPL ) has established and maintains a Comprehensive U.S. Compliance Program on behalf of itself and its

More information

Considerations for Developing a Health Data Analytics Strategy

Considerations for Developing a Health Data Analytics Strategy Considerations for Developing a Health Data Analytics Strategy Hassan Naeem Manager PriceWaterhouseCoopers October 7, 2016 Health data analytics agenda Topic Pg. Analytics Strategy 3 Industry Overview

More information

Accelerated Learning Healthcare Compliance and Policy Applications

Accelerated Learning Healthcare Compliance and Policy Applications Accelerated Learning Healthcare Compliance and Policy Applications Pamela Hrubey Crowe Horwath LLP Sergio Alegre Osmotica Pharmaceutical Dan O Connor PharmaCertify by NXLevel Solutions L. Stephan Vincze

More information

UK STEWARDSHIP CODE RESPONSE BY GENERATION INVESTMENT MANAGEMENT LLP OCTOBER 2016

UK STEWARDSHIP CODE RESPONSE BY GENERATION INVESTMENT MANAGEMENT LLP OCTOBER 2016 UK STEWARDSHIP CODE RESPONSE BY GENERATION INVESTMENT MANAGEMENT LLP OCTOBER 2016 THE UK STEWARDSHIP CODE The UK Stewardship Code (the Code ) was published by the (UK) Financial Reporting Council in 2010

More information

NATIONAL BANK OF FUJAIRAH THE GOVERNANCE FRAMEWORK OF THE BOARD OF DIRECTORS

NATIONAL BANK OF FUJAIRAH THE GOVERNANCE FRAMEWORK OF THE BOARD OF DIRECTORS NATIONAL BANK OF FUJAIRAH THE GOVERNANCE FRAMEWORK OF THE BOARD OF DIRECTORS COPYRIGHT NBF 2016. ALL RIGHTS RESERVED No part of this document may be reproduced, stored in a retrieval system or transmitted

More information

FDA's New Import Program for Strict Precision

FDA's New Import Program for Strict Precision FDA's New Import Program for 2019 - Strict Precision *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The FDA continues to change its import program to better manage new problems

More information

Enterprise Risk Management Framework

Enterprise Risk Management Framework Enterprise Risk Management Framework 2018 Johnson & Johnson 1 2 Introduction In order to deliver value to our consumers, patients, caregivers, employees, communities and shareholders, we at Johnson & Johnson

More information

River City Medical Group ANTIFRAUD PLAN

River City Medical Group ANTIFRAUD PLAN ANTIFRAUD PLAN INTRODUCTION (RCMG) has developed an antifraud plan (the ) in compliance with Section 1348 of the California Health and Safety Code, the Centers for Medicare and Medicaid Service, and the

More information

IT Optimization Award

IT Optimization Award IT leaders are asked to build the plane while flying it and promise a smooth ride. From modernization and standardization to rationalizing and aligning application, vendor and project portfolios, IT must

More information

The Role of Oversight and Monitoring and the Use of Analytics to Increase Effectiveness of your Compliance Program

The Role of Oversight and Monitoring and the Use of Analytics to Increase Effectiveness of your Compliance Program The Role of Oversight and Monitoring and the Use of Analytics to Increase Effectiveness of your Compliance Program Presented by: David Curé, Vice President and Chief Auditor Christopher Price, Sr. Director,

More information

A COMPLIANCE SOLUTION DESIGNED TO HELP PLANS MEET CMS REQUIREMENTS

A COMPLIANCE SOLUTION DESIGNED TO HELP PLANS MEET CMS REQUIREMENTS A COMPLIANCE SOLUTION DESIGNED TO HELP PLANS MEET CMS REQUIREMENTS Founded on the Common Conditions, Improvement Strategies, and Best Practices based on 2013 Program Audit Reviews HPMS memo, dated August

More information

CORE VALUES AND CODE OF CONDUCT

CORE VALUES AND CODE OF CONDUCT CORE VALUES AND CODE OF CONDUCT CORE VALUES AND CODE OF CONDUCT Colorado Access, its subsidiaries and affiliated entities, are dedicated to providing access to high quality healthcare services to members

More information